Vanguard Group Inc. Grows Position in Axon Enterprise, Inc $AXON

Vanguard Group Inc. raised its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 3.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,937,260 shares of the biotechnology company’s stock after acquiring an additional 305,252 shares during the quarter. Vanguard Group Inc. owned 11.39% of Axon Enterprise worth $7,399,515,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Westside Investment Management Inc. increased its holdings in shares of Axon Enterprise by 4.8% in the 2nd quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company’s stock valued at $225,000 after purchasing an additional 13 shares in the last quarter. CVA Family Office LLC grew its position in Axon Enterprise by 26.9% during the second quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock worth $55,000 after buying an additional 14 shares during the period. LaSalle St. Investment Advisors LLC increased its holdings in Axon Enterprise by 2.1% in the first quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company’s stock valued at $408,000 after buying an additional 16 shares in the last quarter. STF Management LP lifted its position in shares of Axon Enterprise by 1.4% during the 2nd quarter. STF Management LP now owns 1,164 shares of the biotechnology company’s stock valued at $964,000 after acquiring an additional 16 shares during the period. Finally, Hemington Wealth Management lifted its position in shares of Axon Enterprise by 70.8% during the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 17 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on AXON shares. Raymond James Financial reaffirmed an “outperform” rating and issued a $855.00 price objective (up from $645.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Weiss Ratings reissued a “hold (c-)” rating on shares of Axon Enterprise in a report on Thursday, November 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $870.00 price target on shares of Axon Enterprise in a research note on Wednesday, September 24th. Piper Sandler decreased their price objective on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Finally, Cowen reissued a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, November 5th. Fifteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $814.00.

Insider Activity

In other news, Director Jeri Williams sold 100 shares of the business’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $752.54, for a total value of $75,254.00. Following the completion of the transaction, the director owned 1,416 shares of the company’s stock, valued at $1,065,596.64. The trade was a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Brittany Bagley sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $610.00, for a total transaction of $1,525,000.00. Following the sale, the chief financial officer owned 91,092 shares in the company, valued at approximately $55,566,120. This trade represents a 2.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 38,622 shares of company stock valued at $26,439,364. 4.40% of the stock is owned by corporate insiders.

Axon Enterprise Stock Performance

Axon Enterprise stock opened at $533.77 on Wednesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. Axon Enterprise, Inc has a fifty-two week low of $469.24 and a fifty-two week high of $885.91. The stock has a fifty day moving average of $694.97 and a two-hundred day moving average of $734.66. The company has a market capitalization of $42.12 billion, a price-to-earnings ratio of 131.80, a PEG ratio of 29.49 and a beta of 1.45.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The company had revenue of $710.64 million for the quarter, compared to analyst estimates of $704.83 million. During the same period in the previous year, the business earned $1.45 EPS. The firm’s revenue was up 30.6% on a year-over-year basis. On average, analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.